2024 in Review: Groundbreaking Advances in HIV Prevention, Cancer Therapies, and More
The year 2024 has been marked by significant breakthroughs in the realm of health, from innovations in HIV prevention and CAR-T cell therapies for solid tumors to promising results in cancer vaccines and new techniques for treating paraplegia. These novel therapeutic approaches are transforming the medical landscape and offering new hopes in the treatment of complex diseases.
HIV Prevention Tops the Charts
In 2024, the Purpose-2 clinical trial highlighted lenacapavir as an effective and long-lasting HIV prevention method. With just two annual doses, this option reduces infection risk by 96%, outperforming daily oral prophylaxis. According to the study’s lead author, Colleen Kelley, the drug will improve treatment adherence and is a critical advancement in the fight against HIV.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) hailed lenacapavir as a revolutionary tool to globally reduce new infections. However, they cautioned that its success hinges on ensuring equitable access.
A World-First: HIV Remission Without CCR5 Delta32 Mutant Donor
In September 2024, history was made when the ‘Geneva Patient’ joined the ranks of individuals who have achieved HIV remission following a stem cell transplant. Notably, this is the first case without the donor carrying the CCR5 delta32 mutation, known for conferring protection against HIV infection.
After 32 months free of detectable viral load following antiretroviral therapy interruption, the ‘Geneva Patient’ made headlines. This milestone was achieved as part of the IciStem consortium, led by University Hospitals of Geneva and the Pasteur Institute.
CAR-T Therapies Tackle Solid Tumors
CAR-T cell therapies have taken a significant step in treating pediatric solid tumors. In a Stanford Medicine trial, nine out of 11 patients with brain tumors experienced significant improvements, including a complete remission in one case. These results, published in Nature, represent a turning point in widening CAR-T use beyond hematological cancers.
Paraplegia Patients Walk Again
One of the most remarkable news in 2024 was the successful restoration of walking ability in two individuals with partial spinal cord injuries, thanks to deep brain stimulation (DBS) in the lateral hypothalamus. Researchers from the EPFL (Switzerland) and CHUV (Switzerland) discovered that this brain region plays an unanticipated role in motor capacity.
By applying DBS to this area, they enhanced the patients’ mobility not only during rehabilitation but also in the long term, even after stimulation ceased.
Promising Cancer Vaccines
The year 2024 has also brought encouraging advancements in cancer vaccine research. A clinical trial using a neoantigen DNA vaccine in non-metastatic, triple-negative breast cancer patients showed promising results. Out of 18 participants, 14 showed immune responses to the vaccine, and after three years, 16 patients remained cancer-free.
Meanwhile, in non-small cell lung cancer, patients at Hospital Universitari i Politècnic La Fe and Consorci Hospitalari Provincial de Castellón received the BNT116 vaccine as part of an international research study. This vaccine aims to boost the body’s immune response against tumors, potentially leading to durable and less toxic outcomes compared to chemotherapy.
In pancreatic cancer, researchers at Memorial Sloan Kettering Cancer Center presented new phase I clinical trial results for an mRNA-based therapeutic vaccine, called autogene cevumeran. In certain patients, the vaccine activated persistent immune cells and correlated with a reduced risk of cancer recurrence.
These groundbreaking developments in HIV prevention, cancer therapies, and more demonstrate the incredible potential of scientific innovation in transforming lives and redefining what’s possible in healthcare.
